BMY » Topics » Gain on sale of product lines and businesses

This excerpt taken from the BMY 8-K filed Apr 28, 2009.

Gain on sale of product lines and businesses

 

   

The gain in 2008 was primarily attributable to the sale of the mature brands businesses in Egypt.

 

   

The gain in 2007 was attributed to the sale of the BUFFERIN* and EXCEDRIN* brands in Japan, Asia (excluding China and Taiwan) and certain Oceanic countries, as well as certain assets related to U.S. dermatology products.

 

   

The gain in 2006 was attributed to the sale of inventory, patent and intellectual property rights related to DOVONEX*.

 

   

For additional information on these transactions, see “Financial Statements—Note 4. Acquisitions and Divestitures.”

These excerpts taken from the BMY 10-K filed Feb 20, 2009.

Gain on sale of product lines and businesses

 

   

The gain in 2008 was primarily attributable to the sale of the mature brands businesses in Egypt.

 

   

The gain in 2007 was attributed to the sale of the BUFFERIN* and EXCEDRIN* brands in Japan, Asia (excluding China and Taiwan) and certain Oceanic countries, as well as certain assets related to U.S. dermatology products.

 

   

The gain in 2006 was attributed to the sale of inventory, patent and intellectual property rights related to DOVONEX*.

 

   

For additional information on these transactions, see “Item 8. Financial Statements—Note 4. Acquisitions and Divestitures.”

Gain on sale of product lines and businesses

 







  

The gain in 2008 was primarily attributable to the sale of the mature brands businesses in Egypt.

STYLE="font-size:6px;margin-top:0px;margin-bottom:0px"> 







  

The gain in 2007 was attributed to the sale of the BUFFERIN* and EXCEDRIN* brands in Japan, Asia (excluding China and Taiwan) and certain Oceanic countries, as
well as certain assets related to U.S. dermatology products.

 







  

The gain in 2006 was attributed to the sale of inventory, patent and intellectual property rights related to DOVONEX*.

STYLE="font-size:6px;margin-top:0px;margin-bottom:0px"> 







  

For additional information on these transactions, see “Item 8. Financial Statements—Note 4. Acquisitions and Divestitures.”

Wikinvest © 2006, 2007, 2008, 2009, 2010, 2011, 2012. Use of this site is subject to express Terms of Service, Privacy Policy, and Disclaimer. By continuing past this page, you agree to abide by these terms. Any information provided by Wikinvest, including but not limited to company data, competitors, business analysis, market share, sales revenues and other operating metrics, earnings call analysis, conference call transcripts, industry information, or price targets should not be construed as research, trading tips or recommendations, or investment advice and is provided with no warrants as to its accuracy. Stock market data, including US and International equity symbols, stock quotes, share prices, earnings ratios, and other fundamental data is provided by data partners. Stock market quotes delayed at least 15 minutes for NASDAQ, 20 mins for NYSE and AMEX. Market data by Xignite. See data providers for more details. Company names, products, services and branding cited herein may be trademarks or registered trademarks of their respective owners. The use of trademarks or service marks of another is not a representation that the other is affiliated with, sponsors, is sponsored by, endorses, or is endorsed by Wikinvest.
Powered by MediaWiki